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Highlights  
• 27 novel BSCA derivatives were designed and synthesized 
• Compound 7 potently inhibited cancer cell viability and showed high 
selectivity. 
• Compound 7 neither induced apoptosis nor had effect on cell cycle 
progression. 
• Compound 9 showed significant high radical scavenging activity.  
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Abstract 
Twenty-seven novel benzo[c][1,2,5]selenadiazole-5-carboxylic acid (BSCA) derivatives 
were designed and synthesized. Anti-proliferative activity of these structures was tested 
in vitro against a panel of five human cancer cell lines, including prostate (PC-3), colon 
(HT-29), leukemia (CCRF-CEM), lung (HTB-54) and breast (MCF-7). Four 
compounds (5, 6, 7 and 19) showed potent inhibitory activity with GI50 values below 10 
µM in at least one of the cancer cell lines. The selectivity of these compounds was 
further examined in two non-malignant cell lines derived from breast (184B5) and lung 
(BEAS-2B). Compound 7 exhibited promising anti-proliferative activity (GI50 = 3.7 
µM) in MCF-7 cells, together with high selectivity index (SI>27.1).  
The induction of cell death by compound 7 was independent of the apoptotic process 
and it did not affect cell cycle progression either. Likewise, radical scavenging 
properties of the new selenadiazole derivatives were confirmed by testing their ability to 
scavenge DPPH radicals. Four compounds (1, 2, 8 and 9) showed potent radical 
scavenging activity, compound 9 being the most effective. Overall, while compound 7 
was identified as the most cell growth inhibitory agent and selectively toxic to cancer 
cells, compound 9 proved to be the most potent antioxidant among the selenadiazole 
derivatives synthesized. This series of compounds can serve as an excellent scaffold to 
achieve new and potent antioxidant compounds useful for several diseases, i.e. cancer, 
neurodegenerative, heart diseases and leishmaniasis, considering the high radical 
scavenging activity and low toxicity showed by most of the compounds. 
Keywords: Anti-proliferative activity, radical scavenging, selenadiazole, selenium. 
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1. Introduction 
Cancer is a major public health problem worldwide due to its high incidence, morbidity 
and mortality [1]. According to the American Cancer Society, 1,735,350 new cancer 
cases are projected to occur in the United States in 2018 [2], the most prevalent being 
prostate, breast, lung, and colorectal cancers [3].  
There are many different types of cancer treatments, including surgery, radiation 
therapy, and/or systemic therapy (e.g., chemotherapy, immunotherapy). Chemotherapy 
is an effective treatment against cancer but is often associated with undesired side 
effects, making the seeking of new chemotherapies a priority. Over the last decade, 
selenium (Se) compounds have been demonstrated to have inhibitory effects on cancer 
cell growth and proliferation. Many mechanisms of action have been identified, 
including the induction of apoptosis, the modulation of the activity of some kinases, 
antioxidant effects mainly through selenoproteins [4], or a combination of these and 
other mechanisms [5, 6]. Several chemical entities have been identified: methylseleno 
derivatives such as methylseleninic acid and selenomethionine, isoselenocyanates, 
selenosemicarbazones, selenourea scaffolds, selenocyanates and diselenides, or sugar-
conjugated Se analogues [7-9] as attractive scaffolds for the development of new 
anticancer agents. 
Recently, fused selenoheteroaryl derivatives have received great attention due to their 
possible usefulness as therapeutic drugs for cancer treatment. Some representative 
examples include 2-Phenyl-1,2-benzisoselenazol-3[2H]-one (ebselen, EBS) [10], 2,2'-
(1,2-Ethanediyl)bis(1,2-benzoselenazol-3[2H]-one) (ethaselen, BBSKE) [11] and 1,2,5-
selenadiazole derivatives [12] (Figure 1). EBS shows high antioxidant capacity through 
the catalysis of several essential reactions for the protection of cellular components 
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from oxidative and free radical damage, acting as a mimetic of glutathione peroxidase 
[13]. Besides, it is noteworthy for its excellent pharmacological profile as well as for its 
therapeutic safety as demonstrated by outcomes of Phase II clinical trials for prevention 
of noise-induced hearing loss [14].  
On the other hand, BBSKE has demonstrated antioxidant and anti-inflammatory 
activities, as well as important antitumoral effects in lung [11] and colon cancer models, 
alone or in combination with cisplatin or sunitinib, through apoptosis induction [15, 16]. 
Furthermore, it inhibited the proliferation of PC-3 and DU-145 prostate cancer cell lines 
by cell cycle arrest at the S phase and the induction of apoptosis [17]. In addition, it 
presents an excellent pharmacological profile, as shown in Phase I clinical trials [18]. 
Other well documented seleno heteroaryl derivatives are 1,2,5-selenadiazole derivatives 
(Figure 1), that have been identified as novel agents with anti-proliferative effect 
against human cancer cells through the induction of apoptosis or cell cycle arrest with 
the involvement of oxidative stress. Among them, 4-(benzo[c][1,2,5]selenadiazol-6-yl)-
benzene-1,2-diamine (SD-1 in Figure 1) is a potent apoptosis inducer in glioma acting 
through the mitochondrial pathway [19]. Moreover, these 1,2,5-selenadiazole 
compounds have shown to be less toxic to non-tumoral cells [12, 20, 21]. There have 
been many reports related to structural modifications in this chemical scaffold, 
particularly at position “5”. So, Xie et al. [22] described novel 5-susbstituted 
selenadiazoles (SD-2 in Figure 1) as apoptosis inducers in A375 human melanoma 
cells, with some of them (SD-3 in Figure 1) acting as intracellular redox balance 
disruptors [20]. In addition, the introduction of simple groups, i.e. 5-methyl or 5-nitro 
(SD-4 in Figure 1), enhanced the anticancer activity alleviating the toxicity to the main 
organs [21]. On the other hand, some of these 5-functionalized selenadiazole derivatives 
(SD-3 in Figure 1) have demonstrated better anti-proliferative activity and higher 
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stability than the reference drug mitomycin, a clinically used anti-bladder cancer drug 
[12]. 
 
Figure 1. Structures of EBS, BBSKE and 5-substituted 1,2,5-selenadiazole. 
Based on the above facts and as a continuation of our previous work [23], we optimized 
the bioactive entity benzo[c][1,2,5]selenadiazol-5-carboxylic acid (BSCA) by 
manipulating the “5” position with a wide variety of moieties (compounds 1-27, Figure 
2) using an amide linkage. The amide linkage was chosen because of it plays a major 
role in biological systems, including peptides and proteins [24]. Likewise, this 
functionality is widely used in medicinal chemistry and it is present in numerous 
anticancer drugs such as flutamide, bicalutamide and sorafenib [25, 26]. 
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Figure 2. General structure of the novel selenadiazole compounds. 
All the synthesized compounds were tested in vitro against a panel of five human tumor 
cell lines and two non-malignant cell lines in order to determine their anti-proliferative 
activity and their selectivity. Likewise, the capability of the synthesized compounds to 
interact with the stable radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) was examined. 
The most active and selective compound (compound 7) was further evaluated for its 
apoptotic effects and cell cycle distribution. The structure of this compound was 
confirmed by X-ray diffraction. 
2. Results and discussion  
2.1. Design 
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The novel BSCA analogs were designed by optimizing the parent scaffold by 
manipulating the “5” position with a variety of moieties using the following criteria: 
a) Several electron-withdrawing or electron-donating groups were substituted in 
the phenyl ring in order to modulate the electronic distribution. Moreover, 
several chemical Se forms, with proven antitumoral effects, e. g. selenol [27] 
and methylseleno [28] were also incorporated in “para” position of the phenyl 
ring. 
b) Modulation of the length of the linker between the amide and R groups, from 0 
to 4 methylenes (carbon atoms), with the aim of finding the optimal chain length 
required for activity.  
c) Several heterocycles (mono- and bi-cyclic) with proven cytotoxic effects, such 
as 2-aminothiazole [29, 30], aminoquinoline [31-33] and 2-aminobenzothiazole 
[34, 35], which also have antioxidant capacity [36]. 
d) Alkyl, cycloalkyl and hydroxyalkyl chains in order to modulate the lipophilicity 
along with the entropy of the molecules. 
e) Finally, a symmetric bi-functionalized amine was used to obtain compound 27, 
in order to evaluate whether the presence of a second selenadiazole ring would 
impact on the antitumor activity. 
2.2. Chemistry  
The synthetic procedures for the preparation of the targeted compounds (1-27) are 
summarized in Schemes 1 and 2. The benzo[c][1,2,5]selenadiazole-5-carboxylic acid 
(BSCA) was obtained as previously reported by us [23]. Chlorination of this acid with 
thionyl chloride, followed by reaction with the corresponding amines at room 
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temperature in dry chloroform and 1 equivalent of triethylamine have been used to 
prepare compounds 1-27. The starting amines that are not commercially available, such 
as 4-(methylselanyl)aniline (7i) and 4-aminobenzeneselenol (8i), were synthesized as 
shown in Scheme 2. The amine 7i was synthesized by treating a methanolic solution of 
4-Aminophenylselenocyanate and sodium hydroxide (0.4 N) with iodomethane in a 
1:1.5 molar ratio at room temperature for 40 min. 4-Aminophenylselenocyanate was 
prepared following a previously described synthetic procedure [23]. The synthetic route 
for amine 8i was based on the reaction between 4-bromoaniline and selenourea in a 
1:1.1 molar ratio at reflux in absolute ethanol as solvent for 2 h. 
 
Scheme 1. General schematic for the synthesis of novel BSCA derivatives (1-27). 
 
Scheme 2. Schematic for the synthesis of amines 7i and 8i. 
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The structures of all the compounds were confirmed using spectroscopic methods (IR, 
1H-NMR, 13C-NMR) and elemental analyses, as described in the Experimental Section. 
In general, the IR spectra of the compounds displayed absorption bands around 3395-
3093 cm-1 originated from the N-H stretching vibration. The strong bands between 1689 
and 1620 cm-1 corresponded to carbonyl bonds stretching. Inspection of 1H-NMR 
spectra revealed one sharp peak in the range of 12.96-8.18 ppm due to the presence of 
the secondary amide proton. The presence of methylene as linker between the amide 
group and phenyl ring led to a decrease in the chemical shift of this sharp peak from 
10.56 ppm (compound 1) to 9.37, 8.90, 8.82 and 8.78 ppm (compounds 20, 22, 23 and 
25, respectively). The proton signals for the heteroaryl ring containing Se appear as a 
singlet between 8.69 and 5.64 ppm, and two multiplets from 7.36 to 8.72 ppm. The 
chemical shift of the methyl group attached to the chalcogen elements (oxygen, sulfur 
or Se) appear at 3.76 (compounds 5), 2.48 (compound 6) and 2.34 ppm (compound 7), 
respectively. For the methylene linker (-CH2-) directly attached to oxygen and nitrogen 
atoms, the proton signals show in the range of 3.51-3.29 ppm, and the rest of protons for 
other methylene linkers appear at higher fields (1.76-1.48 ppm). Similarly, in the 13C-
NMR spectra, the chemical shifts appeared between 122.72 and 37.71 ppm while 
methylene groups signals were observed in 33.16-26.59 ppm region.  
2.3.  Biological evaluation  
2.3.1. Anti-proliferative activity  
All the newly synthesized compounds were screened for their anti-proliferative activity 
against a panel of five human tumor cell lines: lymphocytic leukemia (CCRF-CEM), 
lung carcinoma (HTB-54), colon carcinoma (HT-29), prostate adenocarcinoma (PC-3) 
and breast adenocarcinoma (MCF-7). The in vitro inhibition of cell viability was 
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analyzed by a colorimetric microassay based on the reduction of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) according to a method previously 
described [37]. The five cell lines were treated with each compound for 72 h at two 
concentrations (100 µM and 10 µM). Compound 21 was not tested at 100 µM due to 
solubility problems. The data are expressed as percentage of cell growth ± SEM at least 
3 independent experiments performed in quadruplicates (Table S1). Results at 10 µM 
concentration are summarized in Figure 3. 
 
Figure 3. Anti-proliferative effect of synthesized compounds 1 – 6 (A), 7 – 13 (B), 14 – 
20 (C) and 21 – 27 (D) on five human cancer cell lines after 72 h of treatment with a 
dose of 10 µM for each compound.  
As shown in Figure 3, some compounds were active under our experimental conditions, 
MCF-7 cells being the most sensitive cells. These results allowed us to determine some 
preliminary structure-activity relationships, since: 
a) The length of the linker between the phenyl ring and the amide group seems 
not to be important for inhibition of cell viability, as no significant 
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differences were observed with the increase of the linker length (compounds 
1, 20, 22, 23 and 25).  
b) Among the different substituents on the phenyl ring, methylchalcogen 
(methoxy, methylthio, methylseleno) groups seemed to be the most active 
ones (compounds 5, 6 and 7 respectively). Nevertheless, the presence of 
three methoxy groups leads to a lower anti-proliferative effect (compound 
10). 
c) Great differences in the cell viability can be observed among mono- and bi-
cyclic heterocycles with proven cytotoxic effects. Thus, compound 19, with 
a benzothiazole substituent, inhibited viability of MCF-7 and HTB-54 cells, 
while compound 16, with a thiazole group, showed negligible effect against 
all tested cell lines.  
d) The incorporation of nitrogen atom into a six-member cycle (piperidyl or 
piperazinyl in compounds 13 and 27, respectively) in the “5” position of the 
selenadiazolic core seems to decrease the inhibitory effect of these 
derivatives as compared to the analog carbocyclic substituent (cyclohexyl in 
compound 12).  
As shown in Figure 3, compounds 5, 6, 7 and 19 were found to be the most active, with 
reduction of the cell growth by >50%, after 72 h of treatment at 10 µM, in at least two 
cell lines. They were further tested at four different concentrations (1, 10, 50 and 100 
µM), in order to establish their dose-response curve. As a guide with regard to 
selectivity, these compounds were further examined for toxicity in two non-malignant 
cell lines, one established from normal breast tissue (184B5) and another established 
from normal bronchial epithelium (BEAS-2B). Results are expressed as GI50, TGI, 
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LC50, and selectivity index (SI) that was calculated as the ratio of the GI50 values 
determined for the non-malignant and the tumoral cells (GI50 (184B5)/ GI50 (MCF-7) 
and GI50 (BEAS-2B) / GI50 (HTB-54)). The obtained results are shown in Tables 1 and 
2.  EBS and BBSKE were used as reference drugs, given that both are seleno 
heterocyclic compounds that are currently under clinical trials. BBSKE has been 
synthesized according to a previously reported synthetic route [38], with minor 
modifications described in the supplementary material. Furthermore, doxorubicin [39] 
and etoposide [40, 41] were used as positive controls due to the promising results 
shown by these compounds in vitro and in vivo against different tumor types. 
Table 1. Anti-proliferative activity (average GI50, TGI and LC50 values 
expressed in µM) of selenadiazoles 5, 6, 7 and 19 and EBS, BBSKE, doxorubicin and 
etoposide.  
 Cell lines 
 HT-29 PC-3 CCRF-CEM 
Comp. GI50a TGIb LC50c GI50a TGIb LC50c GI50a TGIb LC50c 
5 40.3 >100 >100 9.8 >100 >100 83.9 >100 >100 
6 53.4 >100 >100 7.4 >100 >100 62.4 >100 >100 
7 8.  8 >100 >100 8.8 >100 >100 85.6 >100 >100 
19 22.3 >100 >100 10.9 >100 >100 >100 >100 >100 
EBS >100 >100 >100 >100 >100 >100 57.1 73.8 90.5 
BBSKE 20.3 33.2 46.0 24.8 39.1 61.0 5.0 8.5 25.4 
doxorubicin 0.1 4.0 25.1 1x10-2 1.2 6.6 3x10-2 7x10-2 0.3 
etoposided 31.6 >100 >100 0.6 4.0 79.4 1.6 50.5 89.9 
 
a
 GI50: concentration that reduces by 50% the growth of treated cells with respect 
to untreated controls. 
b
 TGI: concentration that completely inhibits the cell growth. 
c
 LC50: concentration that kills 50% of the initial cells. 
d NCI data (http://dtp.nci.nih.gov). 
e
 n.d., not determined. 
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Table 2. Anti-proliferative activity (average GI50, TGI and LC50 values 
expressed in µM) and selectivity (calculated SI values) of selenadiazoles 5, 6, 7 and 19 
and EBS, BBSKE, doxorubicin and etoposide.  
 Cell lines 
MCF-7 184B5  HTB-54 BEAS-2B  
Comp. GI50a TGIb LC50c GI50a TGIb LC50c GI50a TGIb LC50c GI50a TGIb LC50c 
5 77.1 >100 >100 >100 >100 >100 18.7 >100 >100 >100 >100 >100 
6 6.2 >100 >100 82.2 >100 >100 18.0 >100 >100 96.4 >100 >100 
7 3.7 86.9 >100 >100 >100 >100 6.3 >100 >100 >100 >100 >100 
19 13.7 72.7 >100 95.6 >100 >100 6.5 >100 >100 >100 >100 >100 
EBS 58.8 >100 >100 30.1 >100 >100 68.6 83.7 98.7 49.5 76.9 >100 
BBSKE 24.2 40.7 72.8 19.2 31.5 43.8 0.79 19.7 30.3 40.9 20.6 30.3 40.0 
doxorubicin 2x10-3 0.3 7.8 1.2 4.6 8.1 574 <1x10-2 1.3 3.5 0.1 1.5 1.8 
etoposidee 19.9 >100 >100 n.d.f n.d. n.d.  n.d. n.d. n.d. n.d. n.d. n.d. 
 
a
 GI50: concentration that reduces by 50% the growth of treated cells with respect to 
untreated controls. 
b
 TGI: concentration that completely inhibits the cell growth. 
c
 LC50: concentration that kills 50% of the initial cells. 
d SI: Selectivity index was calculated as the ratio of the GI50 values determined for the 
non-malignant and the tumoral cells (GI50 (184B5)/ GI50 (MCF-7) and GI50 (BEAS-2B) 
/ GI50 (HTB-54)). 
e NCI data (http://dtp.nci.nih.gov). 
f
 n.d.: not determined. 
As shown in Tables 1 and 2, the selected cancer cell lines present different sensitivity 
profiles to the action of these derivatives. Thus, three compounds (6, 7 and 19) 
effectively inhibited cell viability with GI50 values ranging from 3.7 µM to 18 µM on 
solid tumors (MCF-7, HTB-54 and PC-3 cell lines). However, these compounds were 
inactive against liquid tumors (CCRF-CEM cell line). 
Interestingly, these selenadiazoles exhibited greater anti-proliferative activity than EBS 
in solid tumors, along with higher selectivity indexes (Tables 1 and 2). For instance, 
compounds 6 (GI50 = 6.2 µM) and 7 (GI50 = 3.7 µM) in MCF-7 cells were 9.5 and 15.9 
times more active, respectively, than standard EBS (GI50 = 58.8 µM) and they also 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15 
showed at least 25.9 and 53.1 times higher selectivity index, respectively. Besides, we 
have improved significantly the selectivity indexes of BBSKE and  the potency of 
starting compound, BSCA [23]. 
Moreover, compound 7, with two Se atoms in the structure and having GI50 value of 3.7 
µM and SI > 27.1 in MCF-7 cell line, emerged as the most active and selective 
derivative. Taking into account the effects on the cell viability in the four cancer cell 
lines tested, together with the selectivity (Tables 1 and 2), derivative 7 was selected as 
the lead compound for further biological evaluation. 
2.3.2. Evaluation of cell cycle progression and apoptosis induction 
Various scientific pieces of evidence show that Se compounds are potent antitumor 
agents owing to the induction of apoptosis and the inhibition of cell proliferation [6, 
42]. Compound 7 presented notable inhibitory activity in MCF-7 cells. Therefore, we 
decided to evaluate whether this activity was related to its ability to induce apoptosis 
and / or its effect on the cell cycle progression in MCF-7 cells. This study was 
conducted using the Apo DirectTM kit (BD Pharmigen) [43] based on the TUNEL 
technique with 50 µM of the compound and 72 h of treatment. Camptothecin was 
employed as a positive control.   
As shown in Figure 4, the obtained results demonstrated that the inhibition of cell 
growth was independent both of the apoptotic process and effect on cell cycle 
progression. 
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Figure 4. The activity of compound 7 was independent of apoptotic process and it did 
not modulate cell cycle progression. (A) Bar chart representing the distribution of cells 
in different phases of the cell cycle. (B) Percentage of apoptotic cells were calculated. 
Results are expressed as mean ± SD of at least three independent experiments 
performed in duplicate. *p< 0.05, **p<0.01 and ***p<0.001 with respect the control. 
 
2.4. X-ray crystallography of N-(4-
(methylselanyl)phenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (compound 
7) 
The structure of the lead compound 7 was further confirmed by X-ray diffraction after 
developing a single crystal. Structure and crystal packing of the compound are 
presented in Figures 5 and 6, respectively, and selected interatomic distances and 
angles for this structure are collected in Table S2 and S3 in the Supplementary material.  
The crystal data and structure refinement are listed in Table S4. Hydrogen bonding 
interactions in the crystal structure are given in Table S4. 
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Figure 5. ORTEP diagram of compound 7 with displacement ellipsoids drawn at 50% 
probability level. 
 
Figure 6. Crystal packing of compound 7; some hydrogen atoms were omitted for 
clarity.  
2.5. DPPH free radical-scavenging activity. 
Se compounds, including EBS, show potential chemopreventive activity, which has 
been related to their strong antioxidant activity and their ability to interact with redox 
status of the cell [44]. We decided to evaluate the antioxidant capacity of the 
selenadiazole derivatives using the DPPH  method [45]. 
Determinations were performed at five different concentrations of all the synthesized 
compounds ranging from 3.13 x 10-5 to 0.25 mg/mL and were recorded at different time 
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points (30 ́, 90´, 180´). The ascorbic acid was used as the positive control and the EBS 
was used as a reference compound. 
The results (Figure 7) demonstrated that only four compounds (1, 2, 8 and 9) were able 
to scavenge the DPPH activity, with values above 20% of inhibition at 0.25 mg/mL. 
Compound 9 presented DPPH scavenging values greater than 40% at 0.25 mg/mL, 
displaying greater radical scavenging than EBS. Finally, as shown in Figure 7, these 
compounds exhibited concentration-dependent but not time-dependent radical 
scavenging activity in vitro.  
 
Figure 7.  Analysis of DPPH radical scavenging activity for compounds 1, 2, 8 and 9 
at different concentrations and different time points.  
 
3. Conclusion 
In this study a series of twenty-seven selenadiazole derivatives were synthesized and 
their anti-proliferative effect against five human tumor cell lines by standard MTT 
assay, and antioxidant activity using DPPH test were evaluated. Results demonstrated 
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that “5” position is a favorable site to carry out modifications, given that many analogs 
formed by decorating several substituent over this position through an amide linkage 
displayed better anti-proliferative effects than the parent structure (BSCA). Compounds 
5, 6, 7 and 19 were the most potent in inhibiting viability of at least one cancer cell line 
with GI50 values ranging from 3.7 to 9.8 µM. These activities were 10-fold more potent 
than the reference EBS and the selectivity indexes were greater than EBS and BBSKE. 
Furthermore, the radical scavenging capacity of 1, 2, 8 and 9 was greater than EBS. 
Taking together all the results, compound 7 emerged as the most promising and suggest 
the importance of methylphenylselane group for BSCA scaffold. It is interesting to note 
that contrary to the parent compound (BSCA) and EBS, compound 7 induced cell 
growth inhibition independent of the apoptotic process and without affecting the cell 
cycle progression. This behavior is quite unique and warrants further investigation of 
the in-depth mechanism by which this compound is potently exerting inhibition of 
viability of breast cancer cells while sparing the non-tumoral 184B5 cells. It is clear that 
compound 7, with GI50 greater than 100 µM in normal cells and promising anti-
proliferative activity in MCF-7 cells (GI50 = 3.7 µM) is highly promising as a lead for 
developing effective new chemotherapeutics, particularly for breast cancer.   
Compound 9 on the other hand having better radical scavenging activity than EBS may 
prove to be potent antioxidant. These data suggest that appropriate manipulation of EBS 
structure can lead to a set of promising small drug-like anti-cancer molecules with 
diverse mechanisms of action. Given the greater selectivity and moderate antioxidant 
activity, these compounds can serve as excellent scaffolds to achieve new and potent 
antioxidant compounds useful for several diseases such as cancer, neurodegenerative, 
heart and leishmaniasis diseases. 
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4. Experimental 
4.1. Chemistry 
4.1.1. Material and methods 
Melting points (mp) were determined with a Mettler FP82 + FP80 apparatus 
(Greifensee, Switzerland). The proton (1H) and carbon (13C) NMR spectra were 
recorded on a Bruker 400 Ultrashield™ spectrometer (Rheinstetten, Germany) using 
DMSO-d6 as solvent. The IR spectra were obtained on a Thermo Nicolet FT- IR Nexus 
spectrophotometer with KBr pellets. Purity of all final compounds was 95% or higher 
and was dwtermined by elemental microanalyses carried out on vacuum-dried samples 
using a LECO CHN-900 Elemental Analyzer. Furthermore, Column Chromatography 
using Silica gel 60 (0.040 - 0.063 mm) (Merck KGaA, Darmstadt, Germany) and Thin 
Layer Chromatography (TLC) assays were carried out in Alugram® SIL G/UV254 
sheets (Layer: 0.2 mm) (Macherey-Nagel, Düren, Germany). Chemicals were purchased 
from E. Merck (Darmstadt, Germany), Panreac Química S.A. (Montcada i Reixac, 
Barcelona, Spain), Sigma-Aldrich Química, S.A. (Alcobendas, Madrid, Spain), Acros 
Organics (Janssen Pharmaceuticalaan 3a, 2440 Geel, Belgium) and Lancaster 
(Bischheim-Strasbourg, France). 
4.1.2. Benzo[c][1,2,5]selenadiazole-5-carboxylic acid (BSCA) 
This compound was prepared according to a previously published procedure [23]. 
Briefly, a mixture of 3,4-diaminobenzoic acid and SeO2 was heated at 260 ºC. The 
crude product was washed with water and recrystallized from dioxane.  
4.1.3. General procedure for the synthesis of compounds (1-26) 
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A mixture of BSCA (0.5 g, 2 mmol) and thionyl chloride (20 mL) was stirred at reflux 
for 2 h. The reaction was monitored by IR spectroscopy.  Formation of the acyl chloride 
was confirmed following the wavenumber position in infrared spectroscopy peaks: 
carbonyl group showed up around: 1682 cm-1 and the simple bond of OH group was 
detected around 3448 cm-1 in the starting acid whereas the carbonyl in the acyl chloride 
arose around 1750 cm-1. The resulting acyl chloride was isolated by rotatory 
evaporation of the thionyl chloride under vacuum and the excess of thionyl chloride was 
removed with 3 fractions of toluene (40 mL). The resulting acyl chloride was used 
without further purification. A solution of the corresponding amine (2 mmol) in dry 
chloroform (15 mL) was added to a mixture of acyl chloride (0.5 g, 2 mmol) and 
triethylamine (0.28 mL, 2 mmol) in dry chloroform (40 mL). The mixture was stirred at 
room temperature for 12-48 h. The product was isolated by filtration or by rotatory 
evaporation of the solvent under vacuum and washed with water (3 x 50 mL). Final 
product was purified by washing, recrystallization, or column chromatography.  
4.1.3.1. N-Phenylbenzo[c][1,2,5]selenadiazole-5-carboxamide (1) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and aniline. The resulting product, 
N-phenylbenzo[c][1,2,5]selenadiazole-5-carboxamide (1), did not require further 
purification. A brown powder was obtained. Yield: 40 %; mp: 245-246 ºC. IR (KBr): ν̃ 
3276 (N-H); 1650 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.56 (s, 1H, 
NH), 8.52 (s, 1H, H4), 8.01 (dd, J6-7 = 9.3; J6-4 = 1.7 Hz, 1H, H6), 7.96 (dd, J7-4 = 0.7, 
1H, H7), 7.82 (dd, 2H, J2´-3´ = J6´-5´ = 8.5; J2´-4´ = J6´-4´ = 0.9 Hz, H2´ + H6´), 7.41 - 7.36 
(dd, J3´-4´ = J5´-4´ = 7.6 Hz, 2H, H3´+ H5´), 7.14 (tt, 1H, H4´). 13C NMR (100 MHz, 
DMSO-d6) δ (ppm): 165.6 (C=O), 161.2 + 160.0 (C3 + C8), 139.8 + 135.9 (C5 + C1´), 
129.6 + 128.9 (C3´ + C6 +C5´), 124.9 + 124.0 + 123.5 + 121.3 (C4 + C7 + C2´ + C4´ + 
C6´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1561.1. Elemental analysis calculated 
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(%) for C13H9N3SeO·1/2 H2O: C: 50.17, H: 3.22, N: 13.51; found: C: 50.27, H: 3.34, N: 
13.41. 
4.1.3.2. N-(p-Tolyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (2) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and p-toluidine. The resulting 
product, N-(p-tolyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (2), did not require 
further purification. A brown powder was obtained. Yield: 81 %; mp: 237-238.5 ºC. IR 
(KBr): ν̃ 3284 (N-H), 1645 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.49 
(s, 1H, NH), 8.51 (s, 1H, H4), 8.01 (dd, J6-7 = 9.3; J6-4 = 1.7 Hz, 1H, H6), 7.95 (dd, J7-4 = 
0.5 Hz, 1H, H7), 7.70 (d, J3´-2´ = J5´-6´ = 8.4 Hz, 2H, H3´ + H5´), 7.18 (d, 2H, H2´ + H6´), 
2.29 (s, 3H, -CH3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.4 (C=O), 161.2 + 
160.0 (C3 + C8), 137.3 + 136.0 + 133.8 (C1´ + C4´ + C5), 129.9 + 128.9 (C3´ + C5´ + C6), 
123.9 +123.4 + 121.3 (C4+ C7 + C2´ + C6´), 21.4 (-CH3). 77Se NMR (76 MHz, DMSO-
d6) δ (ppm): 1560.5. Elemental analysis calculated (%) for C14H11N3OSe·1⁄2H2O: C: 
51.70, H: 3.69, N: 12.92; found: C: 52.14, H: 3.98, N: 12.94. 
4.1.3.3. N-(4-Chlorophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (3) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-chloroaniline. The resulting 
product, N-(4-chlorophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (3), did not 
require further purification. A brown powder was obtained. Yield: 63 %; mp: 233-235 
ºC. IR (KBr): ν̃ 3273 (N-H), 1648 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 10.69 (s, 1H, NH), 8.53 (s, 1H, H4), 7.99 (dd, J6-7 = 9.3; J6-4 = 1.7 Hz, 1H, H6), 
7.97 (dd, J7-4 = 0.7 Hz, 1H, H7), 7.86 (d, J2´-3´ = J6´-5´ = 8.8 Hz, 2H, H2´ + H6´), 7.45 (d, 
2H, H3´ + H5´). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.7 (C=O), 161.2 + 160.0 
(C3 + C8), 138.8 + 135.6 (C1´ + C4´), 129.5 + 128.7 + 128.4 (C5 + C6 + C3´ + C5´), 124.0 
+123.6 +122.8 (C4 + C7 + C2´ + C6´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1562.2.  
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Elemental analysis calculated (%) for C12H8ClN3OSe: C: 46.37, H: 2.38, N: 12.48; 
found: C: 46.07, H: 2.74, N: 12.45. 
4.1.3.4. N-(4-Nitrophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (4) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-nitroaniline. The product was 
purified by recrystallization from ethanol. A yellow powder was obtained. Yield: 9 %; 
mp: 245-256 ºC. IR (KBr): ν̃ 3395 (N-H), 1665 (C=O), 1334 cm-1 (NO2). 1H NMR (400 
MHz, DMSO-d6) δ (ppm): 11.08 (s, 1H, NH), 8.57 (s, 1H, H4), 8.29 (d, J3´-2´ = J5´-6´ = 
9.1 Hz, 2H, H3´ + H5´), 8.09 (d, 2H, H2´ + H6´), 8.00 (dd, J6-7 = 9.4; J6-4 = 1.08 Hz, 1H, 
H6), 7.97 (d, 1H, H7). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.3 (C=O), 161.2 + 
159.8 (C3 + C8), 146.0 + 143.5 (C4´ + C1´), 135.0 + 128.6 (C5 + C6), 125.6 + 124.1 
+120.8 (C4 + C7 + C2´ + C3´ + C5´ + C6´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1565.2. Elemental analysis calculated (%) for C13H8N4O3Se·H2O: C: 42.74, H: 2.74, N: 
15.34; found: C: 42.30, H: 3.06, N: 14.90. 
4.1.3.5. N-(4-Methoxyphenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (5) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and p-anisidine. The resulting 
product N-(4-methoxyphenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (5), did not 
require further purification. A yellow powder was obtained.  Yield: 68 %; mp: 233-234 
ºC. IR (KBr): ν̃ 3284 (N-H), 1640 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 10.44 (s, 1H, NH), 8.50 (s, 1H, H4), 8.01 (d, J6-7 = 9.3 Hz, 1H, H6), 7.95 (d, 1H, 
H7), 7.72 (d, J2´-3´ = J6´-5´ =   8 Hz, 2H, H2´ + H6´), 6.96 (d, 2H, H3´ + H5´), 3.76 (s, 3H, 
O-CH3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.1 (C=O), 161.2 + 160.1 (C3 + 
C8 ),156.6 (C4´),  136.0 + 132.9 (C5 + C1´), 128.9 (C6), 123.9 + 123.3 + 122.9 (C4 + C7 
+ C2´ + C6´), 114.7 (C3´ + C5´), 56.1 (O-CH3). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1560.0.  Elemental analysis calculated (%) for C14H11N3O2Se·1/2H2O: C: 48.01, H: 
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3.70, N: 12.00; found: C: 48.09, H: 3.63, N: 11.74. 
4.1.3.6. N-(4-(Methylthio)phenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(6) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-(methylthio)aniline. The 
product was purified by recrystallization from ethanol. A yellow powder was obtained. 
Yield: 21 %; mp: 260-261 ºC. IR (KBr): ν̃ 3093 (N-H), 1647 cm-1 (C=O). 1H NMR (400 
MHz, DMSO-d6) δ (ppm): 10.55 (s, 1H, NH), 8.51 (s, 1H, H4), 8.00 (d, J6-7 = 8 Hz, 1H, 
H6), 7.95 (d, 1H, H7), 7.78 (d, J2´-3´ = J6´-5´ = 8 Hz, 2H, H2´ + H6´), 7.30 (d, 2H, H3´ + 
H5´), 2.48 (s, 3H, S-CH3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.4 (C=O), 
161.2 + 160.0 (C3 + C8), 137.2 + 135.7 + 133.6 (C5 + C1´ + C4´), 128.8 + 127.7 (C6 + 
C3´ + C5´), 124.0 + 123.5 + 121.9 (C4 + C7 + C2´ + C6´), 16.2 (S-CH3). 77Se NMR (76 
MHz, DMSO-d6) δ (ppm): 1561.3. Elemental analysis calculated (%) for 
C14H11N3O2SSe: C: 48.27, H: 3.16, N: 12.07; found: C: 47.77, H: 3.64, N: 11.85. 
4.1.3.7. 4-(Methylselenyl)aniline (7i)  
1.5 mmol of the iodomethane was added to a methanolic solution of 1 mmol of 4-
Aminophenylselenocyanate and 43 mL of sodium hydroxide (0.4 N) and stirred at room 
temperature for 40 min. The reaction medium was then poured into water and the 
product was isolated by filtration and extraction with dichloromethane (3 x 50 mL). The 
product was purified by column chromatography on silica gel using dichloromethane as 
eluent. 4-Aminophenylselenocyanate was prepared following the synthetic procedure 
previously described [23]. Yield: 22 %. IR (KBr): ν̃ 3447-3355 (N-H2), 3213 (=C-H), 
2924 (Se-CH3), 1619-1492 cm-1 (C=C). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.32 (d, 
J3-2 = J5-6 = 8.0 Hz, 2H, H3 + H5), 6.63 (d, 2H, H2 + H6), 2.29 (s, 3H, Se-CH3).  
4.1.3.8. N-(4-(Methylselanyl)phenyl)benzo[c][1,2,5]selenadiazole-5-
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carboxamide (7) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-(methylselenyl)aniline (7i). 
The crude product was purified by washing with chloroform (3 x 15 mL). A yellow 
powder was obtained.  Yield: 38 %; mp: 258-260 ºC. IR (KBr): ν̃ 3296 (N-H), 1647 cm-
1
 (C=O). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.56 (s, 1H, NH), 8.51 (s, 1H, H4), 
8.00 (d, J6-7 = 8.9 Hz, 1H, H6), 7.94 (d, 1H, H7), 7.76 (d, J2´-3´ = J6´-5´ = 7.6 Hz, 2H, H2´ 
+ H6´), 7.42 (d, 2H, H3´ + H5´), 2.34 (s, 3H, Se-CH3). 13C NMR (100 MHz, DMSO-d6) δ 
(ppm): 165.9 (C=O), 161.2 + 160.0 (C3 + C8), 138.1 + 135.7 (C5 + C1´), 131.1 + 128.8 
+ 126.8 (C6 + C3´ + C4´+ C5´), 124.0 + 123.5 + 122.0 (C4 + C7 + C2´ + C6´), 7.8 (Se-
CH3). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1561.5, 189.3. Elemental analysis 
calculated (%) for C14H11N3O2Se2·1/2HCl: C: 40.65, H: 2.66, N: 10.16; found: C: 
41.06, H: 3.09, N: 10.45. 
4.1.3.9. 4-Aminobenzeneselenol (8i) 
12 mmol of the 4-bromoaniline was added to a solution of 13.2 mmol of selenourea in 
15 mL of absolute ethanol and stirred at reflux for 2 h. The product was isolated by 
filtration and washed with water (50 mL). The resulting product, 4-
aminobenzeneselenol (8i), did not require further purification. Yield: 20 %. IR (KBr): ν̃ 
3428-3322 (N-H2), 3232 (=CH-), 2681 (SeH), 1618-1486 cm-1 (C=C). 1H NMR (400 
MHz, DMSO-d6) δ (ppm): 7.11 (d, J3-2 = J5-6 = 8 Hz, 2H, H3 + H5), 6.50 (d, 2H, H2 + 
H6), 5.22 (s, 2H, -NH2), 3.85 (s, 1H, -SeH). Elemental analysis calculated (%) for 
C6H7NSe·1/2H2O: C: 39.79, H: 4.42, N: 7.74; found: C: 40.81, H: 3.89, N: 7.94. 
4.1.3.10. N-(4-Hydroselenophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(8) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-aminobenzeneselenol (8i). 
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The resulting product, N-(4-hydroselenophenyl)benzo[c][1,2,5]selenadiazole-5-
carboxamide (8), did not require further purification. A brown powder was obtained. 
Yield: 80 %; mp: 253.4-255.8 ºC. IR (KBr): ν̃ 3273 (N-H), 1647 cm-1 (C=O). 1H NMR 
(400 MHz, DMSO-d6) δ (ppm): 10.66 (s, 1H, NH), 8.52 (s, 1H, H4), 7.99 (dd, J6-7 = 9.3; 
J6-4 = 1.5 Hz, 1H, H6), 7.97 (dd, J7-6 = 0.7 Hz, 1H, H7), 7.81 (d, J2´-3´ = J6´-5´ = 8 Hz, 2H, 
H2´ + H6´), 7.57 (d, 2H, H3´ + H5´). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.7 
(C=O), 161.2 + 160.0 (C3 + C8), 139.2 +135.6 (C1´ + C5), 132.4 + 128.7 (C6 + C3´ + 
C5´), 124.0 +123.6 + 123.1 + 116.5 (C7 + C4 + C2´ + C4´ + C6´). 77Se NMR (76 MHz, 
DMSO-d6) δ (ppm): 1562.4. Elemental analysis calculated (%) for 
C13H9N3OSe2·1/2H2O: C: 40.01, H: 2.56, N: 10.77; found: C: 39.82, H: 2.29, N: 10.97. 
4.1.3.11. N-(p-Mercaptophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (9) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-aminothiophenol. The 
resulting product, N-(p-mercaptophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(9), did not require further purification. An orange powder was obtained. Yield: 51 %; 
mp: 189.0-188.6 ºC. IR (KBr): ν̃ 3399 (NH), 1654 cm-1 (C=O). 1H NMR (400 MHz, 
DMSO-d6) δ (ppm): 8.49 (s, 1H, H4), 7.99 (d, J7-6 = 9.3 Hz, 1H, H7), 7.91 (dd, J6-4 =   
1.7 Hz, 1H, H6), 7.15 (d, J2´-3´ = J6´-5´ = 8.5 Hz, 2H, H2` + H6´), 6.66 (d, 2H, H3` + H5´), 
5.64 (s, 1H, SH). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 191.9 (C=O), 161.6 + 
159.7 (C3 + C8), 151.5 (C1´) 137.1 + 136.9 (C3´ +C4´ + C5´), 126.6 + 125.0 + 124.0 (C5 
+ C6 + C7) 115.3 + 110.1 (C4 + C2´ + C6´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1573.7. Elemental analysis calculated (%) for C13H9N3OSSe: C: 46.71, H: 2.71, N: 
12.57; found: C: 46.51, H: 3.07, N:12.40. 
4.1.3.12. N-(3,4,5-Trimethoxyphenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(10) 
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From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 3,4,5-trimethoxianiline. The 
resulting product, N-(3,4,5-trimethoxyphenyl)benzo[c][1,2,5]selenadiazole-5-
carboxamide (10), did not require further purification. A yellow powder was obtained. 
Yield: 50 %; mp: 207.2-208.3 ºC. IR (KBr): ν̃ 3272 (N-H), 1651 cm-1 (C=O). 1H NMR 
(400 MHz, DMSO-d6) δ (ppm): 10.45 (s, 1H, NH), 8.53 (s, 1H, H4), 8.02 (d, J6-7 =   9.3 
Hz, 1H, H6), 7.95 (d, 1H, H7), 7.28 (s, 2H, H2´ + H6´), 3.80 (s, 6H, 2OCH3), 3.66 (s, 3H, 
OCH3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.3 (C=O), 161.2 + 160.0 (C3 + 
C8), 153.5 (C3´ + C5´), 136.0 + 135.8 + 134.8 + 128.7 (C5 + C6 + C1´ + C4´), 124.0 + 
123.4 (C7 + C4), 99.0 (C2´ + C6´), 61.0 (OCH3), 56.6 (2OCH3). 77Se NMR (76 MHz, 
DMSO-d6) δ (ppm): 1561.6. Elemental analysis calculated (%) for 
C16H15N3O4Se·1/2H2O: C: 47.89, H: 3.99, N: 10.47; found: C: 47.25, H: 4.40, N: 10.15. 
4.1.3.13. N-Ethylbenzo[c][1,2,5]selenadiazole-5-carboxamide (11)  
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and ethylamine solution. The 
mixture was filtered and the product was isolated by rotatory evaporation of the solvent 
and purified by successive washing with water (50 mL) and hexane (15 mL). A brown 
powder was obtained. Yield: 5 %; mp: 161-164 ºC. IR (KBr): ν̃ 3282 (N-H), 2982 (C 
sp2), 1637 cm-1 (C=O). 1H NMR (400 MHz, CDCl3) δ (ppm): 8.18 (s, 1H, H4), 7.92 (dd, 
J6-7 = 9.3; J6-4 = 1.2 Hz, 1H, H6), 7.90 (d, 1H, H7), 6.34 (s, 1H, NH), 3.62-3.53 (m, 2H, 
-CH2-), 1.32 (t, J CH3-CH2= 7.3 Hz, 3H, -CH3). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 
166.0 (C=O), 161.1 + 160.2 (C3 + C8), 135.6 + 128.7 (C5 + C6), 123.8 +122.7 (C4 + 
C7), 35.2 (-CH2-), 15.5 (-CH3). Elemental “analysis calculated (%) for 
C9H9N3OSe·1/2H2O: C: 41.04, H: 3.80, N: 15.96; found: C: 41.50, H: 3.76, N: 15.23. 
4.1.3.14. N-Cyclohexylbenzo[c][1,2,5]selenadiazole-5-carboxamide (12)  
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and cyclohexylamine. The resulting 
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product, N-cyclohexylbenzo[c][1,2,5]selenadiazole-5-carboxamide (12), did not require 
further purification.  A white powder was obtained. Yield: 63 %; mp: 242.6-246.4 ºC. 
IR (KBr): ν̃ 3303 (N-H), 2934-2854 (cyclohexane, C sp2), 1631 cm-1 (C=O). 1H NMR 
(400 MHz, TFA) δ (ppm): 11.00 (s, 1H, NH), 7.79 (s, 1H, H4), 7.41 (bs, 2H, H6 + H7), 
3.42-3.41 (bs, 1H, H1´), 1.55-1.37 (bs, 2H, H2a´ + H2b´), 1.22-1.21 (bs, 2H, H6a´ + H6b´), 
1.14-1.00 (bs, 1H, H4a´), 0.89-0.81 (bs, 4H, H3a´ +H3b´ +H5a´ +H5b´), 0.65-0.61 (bs, 1H, 
H4b´). Elemental analysis calculated (%) for C13H14N3OSe·1/2H2O: C: 49.37, H: 4.75, 
N: 13.29; found: C: 49.92, H: 5.19, N: 13.27. 
4.1.3.15. N-(Piperidin-1-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (13) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and piperidine. The resulting 
product, N-(piperidin-1-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (13), did not 
require further purification. A brown powder was obtained. Yield: 56 %; mp: 103.3-
101.9 ºC. IR (KBr): ν̃ 2935-2855 (C sp2), 1621 cm-1 (C=O). 1H NMR (400 MHz, 
DMSO-d6) δ (ppm): 7.90 (d, J7-6 = 9.2 Hz, 1H, H7), 7.82 (s, 1H, H4), 7.49 (dd, J6-4=1.5 
Hz, 1H, H6), 3.61 (bs, 2H, 2H1´), 3.33 (bs, 2H, 2H5´), 1.47 + 1.60 (bs+ bs, 6H, 2H2´ + 
2H3´ + 2H4´). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 168.3 (C=O), 160.2 + 159.8 
(C3 + C8), 137.8 (C5) + 129.0 (C6), 124.5 + 121.5 (C4 + C7), 48.9 + 43.2 (C1´ + C5´), 
26.8 + 26.1 + 24.9 (C2´ + C3´ + C4´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1548.0. 
Elemental analysis calculated (%) for C12H13N3OSe: C: 48.99, H: 4.45, N: 14.28; found: 
C: 49.29, H: 4.96, N: 14.44.
 
4.1.3.16. N-(Pyridin-4-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (14)  
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-aminopyridine. The resulting 
product, N-(pyridin-4-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (14), did not 
require further purification. A brown powder was obtained. Yield: 83 %; mp: 277.4-
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280.1 ºC. IR (KBr): ν̃ 3266 (N-H), 1689 cm-1(C=O). 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 10.88 (s, 1H, NH), 8.55 (s, 1H, H4), 8.50 (d, J3´-2´ = J5´-6´ = 5.8 Hz, 2H, H3´ + 
H5´), 7.97 (dd, J6-7 = 9.3; J6-4 = 1.4 Hz, 1H, H6), 7.94 (d, 1H, H7), 7.81 (d, 2H, H2´ + 
H6´). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.6 (C=O), 161.2 + 159.8 (C3 + C8), 
151.2 + 146.6 (C3´ + C5´ + C1´), 135.0 + 128.6 (C5 + C6), 124.1 + 124.0 (C4 + C7), 
114.9 (C2´ + C6´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1565.0. Elemental analysis 
calculated (%) for C12H8N4OSe·1/2HCl: C: 44.83, H: 2.65, N: 17.43; found: C: 45.47, 
H: 2.72, N: 17.46. 
4.1.3.17. N-(4-Morpholinophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(15) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-morpholinoaniline. The 
resulting product, N-(4-morpholinophenyl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(16), did not require further purification. A yellow powder was obtained. Yield: 88 %; 
mp: 278.4-279.8 ºC. IR (KBr): ν̃ 3273 (N-H), 2965-2824 (C sp2), 1644 cm-1 (C=O).  1H 
NMR (400 MHz, DMSO-d6) δ (ppm): 10.41 (s, 1H, NH), 8.48 (s, 1H, H4), 8.00 (dd, J6-7 
= 9.3; J6-4 = 1.7 Hz, 1H, H6), 7.94 (dd, J7-4 = 0.6 Hz, 1H, H7), 7.67 (d, J2´-3´ = J6´-5´ = 9.0 
Hz, 2H, H2` + H6´), 6.96 (d, 2H, H3´ + H5´), 3.74 (t, JCH2-CH2= 4.7 Hz, 4H, 2 -CH2-O-), 
3.08 (t, 4H, 2 -CH2-N-). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 165.0 (C=O), 161.1 
+ 160.1 (C3 + C8), 148.6 + 136.0 (C4´ + C1´), 131.9 + 128.9 (C5 + C6), 123.9 + 123.2 
+122.4 (C4 + C7 + C2´ + C6´), 116.1 (C3´ + C5´), 67.0 (2 -CH2-O-), 49.6 (2 -CH2-N-). 
77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1559.5. Elemental analysis calculated (%) for 
C17H16N4 O2Se·1/2H2O: C: 51.38, H: 4.28, N: 14.10; found: C: 51.26, H: 4.41, N: 
13.89. 
4.1.3.18. N-(Thiazol-2-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (16) 
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From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 2-aminothiazol. The resulting 
product, N-(thiazol-2-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (16), did not 
require further purification. A yellow powder was obtained. Yield: 70 %; mp: 284.2-
285.1 ºC. IR (KBr): ν̃ 3276 (N-H), 1662 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 12.96 (s, 1H, NH), 8.69 (s, 1H, H4), 8.07 (d, J6-7 = 8.7 Hz, 1H, H6), 7.94 (d, 1H, 
H7), 7.59 (s, 1H, H3´), 7.31 (s, 1H, H4´). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 
165.6 (C=O), 161.3+ 159.9 (C3 + C8 + C1´), 138.2 + 133.3 (C5 + C3´), 128.4 (C6), 124.8 
+ 124.1 (C4 + C7), 114.9 (C4´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1565.0. 
Elemental analysis calculated (%) for C10H6N4OSSe: C: 38.84, H: 1.96, N: 18.12; 
found: C: 38.53, H: 2.24, N: 17.82. 
4.1.3.19. N-(4-(p-Methoxybenzyl)piperazin-1-yl)benzo[c][1,2,5]selenadiazol-5-
carboxamide (17) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 1-(4-methoxybencyl)piperazine. 
The reaction mixture was then poured into water and the product was isolated by 
extraction with dichloromethane (3 x 50 mL). The resulting product, N-(4-(p-
methoxybenzyl)piperazin-1-yl)benzo[c][1,2,5]selenadiazol-5-carboxamide (17), did not 
require further purification. A brown powder was obtained. Yield: 45 %; mp: 93.5-94.3 
ºC. IR (KBr): ν̃ 2804-2763 (C sp2), 1622 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ 
(ppm): 7.90 (d, J7-6 = 9.1 Hz, 1H, H7), 7.83 (s, 1H, H4), 7.49 (dd, J6-4 = 1.3 Hz, 1H, H6), 
7.21 (d, J2´-3´ = J6´-5´ = 8.5 Hz, 2H, H2` + H6´), 6.87 (d, 2H, H3´ + H5´), 3.72 (s, 3H, O-
CH3), 3.65 (s, 2H, -CH2-benzyl), 3.43 - 3.42 (bs, 4H, 2 CH2-N1), 2.33 + 2.37 (bs + bs, 
4H, 2 CH2 -N4).13C NMR (100 MHz, DMSO-d6) δ (ppm): 168.4 (C=O), 160.3 + 159.7 
+ 159.2 (C3 + C8 + C4´), 137.2 (C5), 131.1 + 130.3 + 129.1 (C6 + C1´ + C2´ + C6´), 124.5 
+121.9 (C4 + C7), 114.4 (C3´ + C5´), 62.0 (-CH2-benzyl), 55.8 (O-CH3). 77Se NMR (76 
MHz, DMSO-d6) δ (ppm): 1549.3. Elemental analysis calculated (%) for 
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C19H20N4O2Se: C: 54.94, H: 4.85, N: 13.49; found: C: 54.90, H: 5.23, N: 13.44. 
4.1.3.20. N-(Quinolin-8-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide (18) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-aminoquinoline. Final product 
was purified by washing with a mixture of N,N-dimethylformamide/ethanol (5:5; v:v). 
A green powder was obtained.  Yield: 23 %; mp: 188.9-191.1 ºC. IR (KBr): ν̃ 3332 (N-
H), 1660 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.83 (s, 1H, NH), 9.01 
(d, J4´-5´ = 3.5 Hz, 1H, H4´), 8.71 (d, J 6´-5´= 7.5 Hz, 1H, H6´), 8.55 (s, 1H, H4), 8.47 (d, 
J10´-9´ = 8.2 Hz, 1H, H10´), 8.05 (d, J6-7 = 9.4 Hz, 1H, H6), 8.02 (d, 1H, H7), 7.78 (d, 1H, 
H9´), 7.70 (d, J8´-9´=3.9 Hz, 1H, H8´), 7.70 (d, 1H, H5´). 13C NMR (100 MHz, DMSO-d6) 
δ (ppm): 164.6 (C=O), 160.8 + 159.6 (C3 + C8), 149.8 (C4´), 139.1 + 137.3 + 135.3 
+134.4 (C5 + C1´ + C2´ + C6´), 128.4 +127.6 + 127.5 (C6 + C7´ + C9´), 124.2 + 123.3 + 
122.9 (C4 + C7 + C5´ + C10´), 117.9 (C8´). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1564.0. Elemental analysis calculated (%) for C16H10N4OSe·1/2H2O: C: 53.00, H: 2.76, 
N: 15.46; found: C: 53.49, H: 3.14, N: 15.40. 
4.1.3.21. N-(Benzo[d]thiazol-2-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(19) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-aminobenzothiazol. The 
resulting product, N-(benzo[d]thiazol-2-yl)benzo[c][1,2,5]selenadiazole-5-carboxamide 
(20), did not require further purification.  A yellow powder was obtained. Yield: 50 %; 
mp: >300 ºC. IR (KBr): ν̃ 3348 (N-H), 1631 cm-1 (C=O). 1H NMR (400 MHz, DMSO-
d6) δ (ppm): 8.75 (s, 1H, H4), 8.13 (dd, J6-7= 9.4; J6-4= 1.3 Hz, 1H, H6), 8.04 (d, J4´-5´= 
7.6 Hz, 1H, H4´), 7.99 (d, 1H, H7), 7.81 (d, J6-7 = 7.6 Hz, 1H, H7´), 7.49 (t, J6´-5´= 7.6 
Hz, 1H, H6´),7.37 (t, 1H, H5´). Elemental analysis calculated (%) for 
C14H8N4OSSe·1/2H2O: C: 45.62, H: 2.17, N: 15.21; found: C: 45.22, H: 2.50, N: 14.96. 
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4.1.3.22. N-Benzylbenzo[c][1,2,5]selenadiazole-5-carboxamide (20) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 2-benzylamine. The product was 
purified by recrystallization from isopropanol. A yellow powder was obtained.   Yield: 
46 %; mp: 177.5-179ºC. IR (KBr): ν̃ 3272 (N-H), 3026 (C sp-2), 1631 (C=O), 1600-
1400 cm-1 (-HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.37 (t, JNH-CH2 = 5.6 
Hz, 1H, NH), 8.41 (s, 1H, H4), 7.98 (dd, J6-7 = 9.3; J6-4 = 1.2 Hz, 1H, H6), 7.91 (d, 1H, 
H7), 7.39-7.31 (m, 4H, H2´ + H3´ + H5´ + H6´), 7.26 (t, J4´-3´ = J4´-5´ = 6.4 Hz, 1H, H4´), 
4.53 (d, 2H, -CH2-). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.4 (C=O), 161.2 + 
160.2 (C3 + C8), 140.2 + 135.3 (C1´ + C5), 129.2 + 128.7 + 128.2 + 127.7 (C6 + C2´ + 
C3´ + C4´+ C5´+ C6´), 123.9 + 123.0 (C4 + C7), 43.8 (-CH2-). Elemental analysis 
calculated (%) for C14H11N3OSe: C: 53.16, H: 3.48, N: 13.29; found: C: 52.60, H: 3.79, 
N: 13.13. 
4.1.3.23. N-(4-Bromobenzyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (21) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-bromobenzylamine. The 
resulting product, N-(4-bromobenzyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (21), 
did not require further purification.  A white powder was obtained. Yield: 74 %; mp: 
187.8-190 ºC. IR (KBr): ν̃ 3273 (N-H), 1625 cm-1 (C=O). 1H NMR (400 MHz, DMSO-
d6) δ (ppm): 9.38 (t, JNH-CH2 = 5.7 Hz, 1H, NH), 8.41 (s, 1H, H4), 7.96 (dd, J6-7 = 9.3; J6-
4 = 1.4 Hz, 1H, H6), 7.93 (d, 1H, H7), 7.54 (d, J3´-2´ = J5´-6´ = 8.3 Hz, 2H, H3´ + H5´), 7.33 
(d, 2H, H2´ + H6´), 4.50 (d, 2H, -CH2-).13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.4 
(C=O), 161.2 + 160.1 (C3 + C8), 139.7 + 135.2 (C5 + C1´), 132.1 + 130.4 + 128.6 (C6 + 
C3´ + C2´ + C5´ + C6´), 123.9 + 123.07 + 120.7 (C4 + C7 + C4´), 43.2 (-CH2-). 77Se NMR 
(76 MHz, DMSO-d6) δ (ppm): 1559.5. Elemental analysis calculated (%) for 
C14H10BrN3OSe·1/2H2O: C: 41.58, H: 2.72, N: 10.40; found: C: 41.98, H: 2.88, N: 
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10.89. 
4.1.3.24. N-Phenethylbenzo[c][1,2,5]selenadiazole-5-carboxamide (22) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 2-phenylethylamine. The 
product was purified by recrystallization from isopropanol. A yellow powder was 
obtained. Yield: 33 %; mp: 194.1-195 ºC. IR (KBr): ν̃ 3294 (N-H), 3061-3028 (C sp-2), 
1634 (C=O), 1600-1400 cm-1 (-HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 
8.90 (t, JNH-CH2 = 5.3 Hz, 1H, NH), 8.30 (s, 1H, H4), 7.91 (dd, J6-7 = 9.3; J6-4 = 1.5 Hz, 
1H, H6), 7.90 (dd, J7-4 = 0.8 Hz, 1H, H7), 7.34 - 7.26 (m, 4H, H2´ + H3´ + H5´ +H6´), 
7.21 (tt, J4´-3´ = J4´-5 ´= 6.8; J4´-2´ = J4´-6´ = 1.6 Hz, 1H, H4´), 3.54 (q, JCH2-CH2 = JCH2-NH = 
7.4 Hz, 2H, -CH2-NH), 2.89 (t, 2H, -CH2-Ph). 13C NMR (100 MHz, DMSO-d6) δ 
(ppm): 166.3 (C=O), 161.1 + 160.2 (C3 + C8), 140.3 + 135.6 (C5 + C1´), 129.6 +129.2 + 
128.7 + 127.0 (C6 + C2´ + C3´ + C4´ + C5´ + C6´), 123.8 + 122.8 (C4 + C7), 41.9 (-CH2-
NH), 35.8 (-CH2-Ph). Elemental analysis calculated (%) for C15H13N3OSe: C: 54.55, H: 
3.94, N: 12.73; found: C: 54.30, H: 4.32, N: 12.74. 
4.1.3.25. N-(3-Phenylpropyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (23) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 3-phenylpropylamine. The 
resulting product, N-(3-phenylpropyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (23), 
did not require further purification. A brown powder was obtained. Yield: 86 %; mp: 
147-148 ºC. IR (KBr): ν̃ 3288 (N-H), 3024 (C sp-2), 1632 (C=O), 1600-1400 cm-1 (-
HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.82 (t, JNH-CH2 = 4.9 Hz, 1H, NH), 
8.31 (s, 1H, H4), 7.92 (d, J6-7 = 9.3 Hz, 1H, H6), 7.88 (d, 1H, H7), 7.31-7.21 (m, 4H, H2´ 
+ H3´ + H5´ +H6´), 7.17(t, J4´-3´ = J4´-5 ´= 7.0 Hz, 1H, H4´), 3.33 (q, JCH2-CH2 = 7.4 Hz, 2H, 
-CH2-NH), 2.65 (t, 2H, -CH2-Ph), 1.86 (m, 2H, -CH2-CH2-CH2-).13C NMR (100 MHz, 
DMSO-d6) δ (ppm): 166.3 (C=O), 161.1 + 160.2  (C3 + C8), 142.6 + 135.7  (C1´ + C5), 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 34 
129.2 + 129.1 +128.8 + 126.6 (C6 + C2´ + C3´ + C4´ + C5´ + C6´), 123.8 + 122.8 (C4 + 
C7), 33.5 + 31.6  (-CH2-NH + -CH2-CH2-CH2- + -CH2-Ph). 77Se NMR (76 MHz, 
DMSO-d6) δ (ppm): 1557.4. Elemental analysis calculated (%) for C16H15N3OSe·1⁄2 
H2O: C: 54.40, H: 4.53, N: 11.90; found: C: 54.90, H: 4.38, N: 11.80. 
4.1.3.26. N-(3-Hydroxypropyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (24) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 3-amino-1-propanol. The 
product was purified by recrystallization from dicloromethane. Yield: 18 %; mp: 158-
160 ºC. IR (KBr): ν̃ 3295 (N-H), 2948 (C, sp2), 1637 (C=O), 1600-1400 cm-1 (-
HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.76 (t, JNH-CH2 = 5.2 Hz, 1H, NH), 
8.33 (s, 1H, H4), 7.94 (dd, J6-7 = 9.3; J6-4 = 1.5 Hz, 1H, H6), 7.89 (d, 1H, H7), 3.49 (t, 
JCH2-CH2 =5.9 Hz, 2H, -CH2-OH-), 3.36 (q, JCH2-CH2 = 6.7 Hz, 2H, -CH2-NH-), 1.76-1.69 
(m, 2H, -CH2-CH2-CH2-).13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.3 (C=O), 
161.1 + 160.2 (C3 + C8), 135.7 (C5), 128.7 (C6), 123.8 + 122.8 (C4 + C7), 59.5 (-CH2-
OH-), 37.7 + 33.2 (-CH2-NH- + -CH2-CH2-CH2-). 77Se NMR (76 MHz, DMSO-d6) δ 
(ppm): 1557.6. Elemental analysis calculated (%) for C10H11
 
N3O2Se·H2O: C: 39.74, H: 
3.64, N: 13.91; found: C: 39.87, H: 3.74, N: 13.68. 
4.1.3.27. N-(4-Phenylbutyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (25) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-phenylbutylamine. The 
resulting product, N-(4-phenylbutyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (25), 
did not require further purification. A brown powder was obtained. Yield: 78 %; mp: 
170.6-171.1 ºC. IR (KBr): ν̃ 3299 (N-H), 3026 (C, sp-2), 1632 (C=O), 1600-1400 cm-1 (-
HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.78 (t, JNH-CH2 = 5.2 Hz, 1H, NH), 
8.32 (s, 1H, H4), 7.93 (d, J6-7 = 9.3 Hz, 1H, H6), 7.89 (d, 1H, H7), 7.27(t, J2´-3´=J6´-5´=7.5 
Hz, 2H, H2´+ H6), 7.21 (d, 2H, H3´+ H3´), 7.16(t, J4´-3´ = J4´-5 ´=7.1 Hz, 1H, H4´), 3.34 (q, 
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JCH2-CH2 = 6.10 Hz 2H, -CH2- NH), 2.62 (t, JCH2-CH2 =7.17, 2H, -CH2-Ph), 1.61 (m, 4H, -
CH2-CH2-CH2-CH2-). 13C NMR (100 MHz, DMSO-d6) δ (ppm): 166.2 (C=O), 161.1 + 
160.2 (C3 + C8), 143.0 + 135.7 (C5 + C1´), 129.2 + 129.1 + 128.7 + 126.5 (C6 + C2´ 
+C3´ + C4´ + C5´ + C6´), 123.8 + 122.7 (C4 + C7), 35.7 +29.5 + 29.4 (-CH2- NH + NH-
CH2-CH2- + -CH2-CH2-Ph + -CH2-Ph). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1557.6. Elemental analysis calculated (%) for C17H17N3OSe: C: 56.99, H: 4.75, N: 
11.73; found: C: 56.95, H: 5.04, N: 11.49. 
4.1.3.28. N-(4-Hydroxybutyl)benzo[c][1,2,5]selenadiazole-5-carboxamide (26) 
From benzo[c][1,2,5]selenadiazole-5-acyl chloride and 4-amino-1-butanol. The product 
was purified by recrystallization from THF. A white powder was obtained. Yield: 61 %; 
mp: 160-162 ºC. IR (KBr): ν̃ 3293 (N-H), 2943-2867 (C, sp2), 1630 (C=O), 1600-1400 
cm-1 (-HC=CH-). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.76 (t, JNH-CH2 = 5.0 Hz, 
1H, NH), 8.34 (s, 1H, H4), 7.94 (d, J6-7 = 9.2 Hz, 1H, H6), 7.89 (d, 1H, H7), 3.46-3.42 
(m, 2H, -CH2-OH-), 3.34-3.29 (q, JCH2-CH2 = 6.1 Hz, 2H, -CH2- NH-),  1.62-1.56 (m, 
2H, -CH2-CH2-CH2-OH), 1.53-1.48 (m, 2H, -NH-CH2-CH2-CH2-).13C NMR (100 MHz, 
DMSO-d6) δ (ppm): 166.2 (C=O),  161.1 + 160.2 (C3 + C8), 135.7 (C5), + 128.7 (C6), 
123.75 + 122.7  (C7 + -CH2-OH-),  61.3 (-CH2-NH-),  30.9 (-CH2-CH2-CH2-OH), 26.6 
(-NH-CH2-CH2-CH2-). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 1557.5. Elemental 
analysis calculated (%) for C11H13N3O2Se: C: 44.29, H: 4.36, N: 14.09; found: C:44.19, 
H: 4.33, N: 13.61. 
4.1.4. Synthesis of Piperazine-1,4-diylbis(benzo[c][1,2,5]selenadiazol-5-ylmethanone 
(27) 
A mixture of BSCA (0.5 g, 2 mmol) and thionyl chloride (20 mL) was stirred at reflux 
for 2 h. The reaction was monitored by IR spectroscopy. The resulting acyl chloride was 
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isolated by rotatory evaporation of the thionyl chloride under vacuum and the excess of 
thionyl chloride was removed with 3 fractions of toluene (40 mL). The resulting acyl 
chloride was used without further purification. A solution of the piperazine (0.09 g, 1 
mmol) in dry chloroform (15 mL) was added to a mixture of the resulting acyl chloride 
(0.5 g, 2 mmol) and triethylamine (0.28 mL, 2 mmol) in dry chloroform (40 mL). The 
mixture was stirred at room temperature for 72 h. The product was isolated by filtration 
and washed with water (3x 50 mL). The resulting product, piperazine-1,4-
diylbis(benzo[c][1,2,5]selenadiazol-5-ylmethanone (27), did not require further 
purification. A brown powder was obtained. Yield: 99 %; mp: 229.4-231.3 ºC. IR 
(KBr): ν̃ 1620 cm-1 (C=O). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.91 (d, 4H, 2H6 + 
2H7), 7.55 (s, 2H, H4), 3.69-3.57 (bs, 8H, 2 CH2-CH2). 13C NMR (100 MHz, DMSO-
d6) δ (ppm): 168.8 (2C=O), 160.3 + 159.7 (2C3 + 2C8), 136.8 (2C5), 129.1 (2C6), 124.6 
+ 122.2 (2C4 + 2C7), 40.31 (2 CH2-CH2). 77Se NMR (76 MHz, DMSO-d6) δ (ppm): 
1550.3. Elemental analysis calculated (%) for C18H14N6O2Se2·1/2H2O: C: 42.09, H: 
2.92, N: 16.37; found: C: 42.32, H: 3.14, N: 16.03. 
4.2. Biological evaluation 
4.2.1. Anti-proliferative activity 
The cell lines were obtained from the American Type Culture Collection (ATCC). Five 
tumor cell lines (MCF-7, PC-3, HT-29, HTB-54 and CCRF-CEM) were grown in RPMI 
medium (Gibco), supplemented with 10 % fetal bovine serum (FBS; Gibco) and 1 % 
antibiotics (10.00 units/mL penicillin and 10.00 µg /mL streptomycin; Gibco). 184B5 
cells were grown in DMEM / F12 (1 : 1) (1X) + GlutaMAXTM medium (Gibco)  
supplemented with 5 % FBS, 1 % antibiotics and a supplement cocktail containing 1 
mL of hydrocortisone (100 nm; Aldrich), 1 x ITS (Lonza), 10 mL of sodium pyruvate 
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(2 mM; Lonza), 10 µL of EGF (20 ng /mL; Aldrich) and 150 µL of trans-retinoic acid 
(0.3 nM; Aldrich). BEAS-2B were grown in DMEM medium (Gibco), supplemented 
with 10 % FBS and 1 % antibiotics. Cells were preserved in tissue culture flasks at 37 
ºC and 5% CO2. Culture medium was replaced every three days. 
The effect of each compound on cell viability was tested using the MTT assay [46]. 
Each compound was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 0.01 
M. Sterile filtration of the compounds was achieved using 0.2 µM filter disk. Serial 
dilutions were prepared with non-supplemented culture medium. The inhibition of cell 
viability was determined at four different concentration ranging from 1 to 100 µM. 
Cells were seeded at 1 x 104 per well in the case of MCF-7, PC-3, HT-29, HTB-54, 
184B5 and BEAS-2B cells onto flat-bottomed 96-well culture plates and 4 x 104 per 
well in the case of CCRF-CEM cells onto round-bottomed 96-well culture plates. They 
were treated with either DMSO or increasing concentration of the corresponding 
compound for 72 h. Then, they were incubated with 50 µL of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (2 mg /mL stock; Aldrich) for 4 h and 
analyzed for their ability to generate a purple formazan dye. These formazan crystals 
were dissolved in 150 µL of DMSO. The absorbance was measured at a wavelength of 
550 nm and the ratio of viable cells was calculated. Results are expressed as GI50, 
concentration that reduces by 50% the cell growth with respect to untreated controls; 
TGI, concentration that completely inhibits cell growth of treated cells with respect to 
untreated controls; and LC50, concentration that kills 50% of the initial cells. 
Furthermore, the selectivity index (SI) was calculated as the ratio of the GI50 values 
determined for the non-malignant and the tumoral cells (GI50 (184B5)/GI50 (MCF-7) 
and GI50 (BEAS-2B)/GI50 (HTB-54)). Data were obtained from at least three 
independent experiments performed in quadruplicates. 
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4.2.2. Evaluation of cell cycle progression and apoptosis induction 
For the MCF-7 cells, the apoptosis evaluation and cell cycle analysis of the cells were 
determined using the Apo DirectTM kit (BD Pharmingen), based on the TUNEL 
technique, according to the procedure described by the manufacturer. To fix the cells, 
they were suspended in 1% paraformaldehyde in PBS (pH = 7.4) at a concentration of 
1x106 cells/mL and placed on ice for 60 min. Then, cells were centrifuged, washed, 
adjusted to 1x106 cells/mL in 70% ethanol and incubated on ice for 30 min. After 
fixation, the cells were stained. Briefly, the cells were centrifuged, washed and 
resuspended in FITC dUTP-DNA labelling solution and incubated for 60 min at 37 ºC. 
Finally, at the end of the incubation time, the cells were rinsed with 1 mL of the Rinse 
Buffer, and the cells were resuspended in PI/RNase Staining Buffer, incubated for 30 
min at RT, in the dark. These cells were analyzed by flow cytometer (Coulter Epics XL, 
Beckmam Coulter). 
4.3. X-ray crystallography of compound 7 
Single crystals of N-(4-(methylselanyl)phenyl)benzo[c][1,2,5]selenadiazole-5-
carboxamide, (compound 7) were grown from solution of DMSO by slow evaporation. 
A suitable crystal was selected and mounted on a nylon loop using paratone oil, for data 
collection on a 'Bruker SMART APEX CCD' diffractometer. The crystal was kept at 
room temperature (~25 ºC) during data collection. Using Olex2 [47], the structure was 
solved with the XS [48] structure solution program using Direct Methods and refined 
with the XL [48] refinement package using Least Squares minimization. 
4.4. DPPH free radical- scavenging assay 
The DPPH method is one of the most efficient methods for evaluating the radical-
scavenging action by a chain-breaking mechanism [49]. This bioassay is a standard to 
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estimate the antioxidant property of chemicals like novel selenadiazole compounds, 
previously described by Svinyarov [45]. This is based on the reduction of a stable free 
radical, DPPH with the presence of antioxidants, by the donation of a hydrogen atom. 
Then, this reduction of DPPH causes the decrease in its absorbance at 517 nm and we 
can determine the corresponding DPPH radical- scavenging activity.  
A methanolic solution (0.04 mg/mL) of DPPH (Aldrich) was prepared daily and 
protected from light. Besides, each compound was initially dissolved in DMSO at a 
concentration of 1.25 mg/mL and serial dilutions in absolute methanol were prepared 
(0.25, 0.0625, 0.000625, 0.0000625 mg/mL). The blank of colourless sample was 
prepared with DMSO mixed with absolute methanol at the same concentrations of 
DMSO in samples. Nevertheless, for coloured samples, like compound 9, the most 
concentrated dilution was used as a blank. 750 µL of each sample were dissolved in 750 
µL of solution of DPPH, and the control was prepared dissolving 750 µL of each blank 
in 750 µL of solution of DPPH. After 30, 90 and 180 min of incubation at 37 ºC in the 
dark, the absorbance was read against a blank at 517 nm. The ascorbic acid (vitamin C) 
was used as the positive control and the EBS was used as a reference compound. All the 
measurements were carried out in triplicate. Results are expressed as the percentage of 
the radical scavenger, calculated using the following formula:  
a) For colourless samples: 
%	DPPH	radical	scavenging =
					 !"		
			
  
b) For coloured samples: 
%	DPPH	radical	scavenging =
					 !"	 !"		
			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